

Bangladesh Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

| | | | | |
|--|-------------------------|------------|------------|--------------------|
| 1. Country: Bangladesh | | | | |
| 2. Grant number: 1718-BGD-12b-X | | | | |
| 3. Date of Decision Letter: 16 December 2016 | | | | |
| 4. Date of the Partnership Framework Agreement: 24 June 2013 | | | | |
| 5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine | | | | |
| 6. Vaccine type: Pneumococcal | | | | |
| 7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 2 dose(s) per vial , LIQUID | | | | |
| 8. Programme duration¹: 2014 - 2018 | | | | |
| 9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) | | | | |
| | 2014 - 2016 | 2017 | 2018 | Total ² |
| Programme Budget (US\$) | 86,427,000 ³ | 41,724,000 | 33,430,500 | 161,581,500 |
| 10. Vaccine introduction grant (in US\$): Not applicable | | | | |
| 11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴ | | | | |
| Type of supplies to be purchased with Gavi funds in each year | 2014 - 2016 | 2017 | | |
| Number of Pneumococcal vaccines doses | | 12,345,400 | | |
| Annual Amounts (US\$) | 86,427,000 ⁵ | 41,724,000 | | |

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

| 12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF. | | | | | | | | | | | | | | | | | | | | | | | |
|---|-------------------------------|-----------|--|-----------|---|-------------------------|---|-------------------------------|-----------------------|---------|--|------------------------------------|--|--|------------------------|--------|--|-------------------------------|-----------|--|--|-----------|-----------|
| 13. Self-procurement: Not applicable | | | | | | | | | | | | | | | | | | | | | | | |
| <p>14. Co-financing obligations: Reference code: 1718-BGD-12b-X-C</p> <p>According to the co-financing policy, the Country falls within the group Preparatory transition.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2017</th> <th>2018</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>933,600</td> <td>861,200</td> </tr> <tr> <td>Number of AD syringes</td> <td>945,600</td> <td></td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td>10,425</td> <td></td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>2,847,138</td> <td></td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>2,921,500</td> <td>2,694,000</td> </tr> </tbody> </table> | | | Type of supplies to be purchased with Country funds in each year | 2017 | 2018 | Number of vaccine doses | 933,600 | 861,200 | Number of AD syringes | 945,600 | | Number of re-constitution syringes | | | Number of safety boxes | 10,425 | | Value of vaccine doses (US\$) | 2,847,138 | | Total co-financing payments (US\$) (including freight) | 2,921,500 | 2,694,000 |
| Type of supplies to be purchased with Country funds in each year | 2017 | 2018 | | | | | | | | | | | | | | | | | | | | | |
| Number of vaccine doses | 933,600 | 861,200 | | | | | | | | | | | | | | | | | | | | | |
| Number of AD syringes | 945,600 | | | | | | | | | | | | | | | | | | | | | | |
| Number of re-constitution syringes | | | | | | | | | | | | | | | | | | | | | | | |
| Number of safety boxes | 10,425 | | | | | | | | | | | | | | | | | | | | | | |
| Value of vaccine doses (US\$) | 2,847,138 | | | | | | | | | | | | | | | | | | | | | | |
| Total co-financing payments (US\$) (including freight) | 2,921,500 | 2,694,000 | | | | | | | | | | | | | | | | | | | | | |
| 15. Operational support for campaigns: Not applicable | | | | | | | | | | | | | | | | | | | | | | | |
| <p>16. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table> | | | Reports and other information | Due dates | To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | May | In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Secretariat | | | | | | | | | | | | | | | |
| Reports and other information | Due dates | | | | | | | | | | | | | | | | | | | | | | |
| To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received. | May | | | | | | | | | | | | | | | | | | | | | | |
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Secretariat | | | | | | | | | | | | | | | | | | | | | | |
| 17. Financial clarifications: The country is requested to address any recommendations, prioritised needs and strategic actions as described in the High Level Review Panel Report (October 2016). | | | | | | | | | | | | | | | | | | | | | | | |
| 18. Other conditions: Not applicable. | | | | | | | | | | | | | | | | | | | | | | | |

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2016